Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk Mortality (b) 51% Mortality (c) -8% levels Ventilation 48% levels ICU admission 12% levels Hospitalization 1% levels c19early.org/d Jimenez et al. Vitamin D for COVID-19 Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Retrospective 285 patients in Spain (March - May 2020) Lower mortality with vitamin D (p=0.02) Jimenez et al., Nutrients, doi:10.3390/nu13082559 Favors vitamin D Favors control
Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
Jimenez et al., Nutrients, doi:10.3390/nu13082559
Jimenez et al., Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics, Nutrients, doi:10.3390/nu13082559
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 288 hemodialysis patients in Spain, 137 with existing vitamin D treatments (94 with paricalcitol), showing lower mortality with treatment. There was no significant difference in outcomes based on serum levels, however authors do not separate patients that received vitamin D treatment.
risk of death, 50.1% lower, HR 0.50, p = 0.02, treatment 16 of 94 (17.0%), control 65 of 191 (34.0%), NNT 5.9, adjusted per study, paricalcitol treatment, multivariate Cox regression.
risk of death, 50.7% lower, HR 0.49, p = 0.003, all vitamin D derivatives, univariate.
risk of death, 7.7% higher, OR 1.08, p = 0.81, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses: many patients received vitamin D treatment.
risk of mechanical ventilation, 47.5% lower, OR 0.53, p = 0.56, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses: many patients received vitamin D treatment.
risk of ICU admission, 12.2% lower, OR 0.88, p = 0.87, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses: many patients received vitamin D treatment.
risk of hospitalization, 0.8% lower, OR 0.99, p = 0.98, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses: many patients received vitamin D treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jimenez et al., 26 Jul 2021, retrospective, Spain, peer-reviewed, 21 authors, study period 12 March, 2020 - 21 May, 2020, dosage paricalcitol 0.9μg weekly.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics María Dolores Arenas Jimenez 1,2, *, Emilio González-Parra 3 , Marta Riera 1 , Abraham Rincón Bello 4 , Ana López-Herradón 4 , Higini Cao 1 , Sara Hurtado 4 , Silvia Collado 1 , Laura Ribera 4 , Francesc Barbosa 1 , Fabiola Dapena 5 , Vicent Torregrosa 6 , José-Jesús Broseta 5 , Carlos Soto Montañez 6 , Juan F. Navarro-González 7,8,9 , Rosa Ramos 4 , Jordi Bover 10 , Xavier Nogués-Solan 11 , Marta Crespo 1 , Adriana S. Dusso 12,13 and Julio Pascual 1 1 2 3 4 5   Citation: Arenas Jimenez, M.D.; González-Parra, E.; Riera, M.; Rincón Bello, A.; López-Herradón, A.; Cao, 6 7 8 9 H.; Hurtado, S.; Collado, S.; Ribera, L.; Barbosa, F.; et al. Mortality in 10 Hemodialysis Patients with 11 COVID-19, the Effect of Paricalcitol or Calcimimetics. Nutrients 2021, 13, 12 2559. https://doi.org/10.3390/ nu13082559 Academic Editor: Andrea Fabbri Received: 22 June 2021 Accepted: 20 July 2021 Published: 26 July 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). 13 * Department of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain; mriera1@imim.es (M.R.); hcao@psmar.cat (H.C.); scollado@psmar.cat (S.C.); fbarbosa@psmar.cat (F.B.); mcrespo@psmar.cat (M.C.); julpascual@gmail.com (J.P.) Fundación Renal Iñigo Alvarez de Toledo, 28003 Madrid, Spain Fundación Jimenez Díaz, 28040 Madrid, Spain; egonzalezpa@senefro.org Fresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain; abraham.rincon@fmc-ag.com (A.R.B.); ana.lopez@fmc-ag.com (A.L.-H.); sara.hurtado@fmc-ag.com (S.H.); laura.ribera@fmc-ag.com (L.R.); rosa.ramos@fmc-ag.com (R.R.) Department of Nephrology, Consorci Sanitari Alt Penedes Garraf, 08800 Barcelona, Spain; proyectologos1@gmail.com (F.D.); jjbroseta@clinic.cat (J.-J.B.) Department of Nephrology and Kidney Transplantation, Hospital Clinic, 08036 Barcelona, Spain; VTORRE@clinic.cat (V.T.); csoto@csg.cat (C.S.M.) Research Division and Department of Nephrology, Hospital Nuestra Señora de la Candelaria, 38010 Santa Cruz de Tenerife, Spain; jnavgon@gobiernodecanarias.org Instituto de Tecnologías Biomédicas, Universidad de La Laguna, 38010 Tenerife, Spain Red de Investigación Renal (REDINREN–RD16/0009/0022), Instituto de Salud Carlos III, 28029 Madrid, Spain Department of Nephrology, Hospital Can Ruti, 08916 Barcelona, Spain; jbover@fundacio-puigvert.es Department of Internal Medicine, Hospital del Mar, Institut Mar for Medical Research, CIBERFES, 08003 Barcelona, Spain; xnogues@psmar.cat Bone and Mineral Research Unit, Instituto de Investigaciones Sanitarias del Principado de Asturias, 33011 Oviedo, Spain; adriana.dusso@gmail.com Department of Internal Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA Correspondence: lola@olemiswebs.net Abstract: Background. In COVID-19 patients, low serum vitamin D (VD) levels have been associated with severe acute respiratory failure and poor prognosis. In regular..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit